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Neuroleptic drugs are essential in the treatment of 
schizophrenia and many other psychiatric disorders. These 
drugs do however cause a wide range of side effects which can 
be very distressing to patients. In particular the acute 
neurological side effects of parkinsonism, akathisia and 
dystonia, which are termed extrapyramidal syndromes, can be a 
limiting factor in the use of these drugs (Weiden et al 1987). 
Fort Napier Hospital is a large psychiatric referral hospital 
and the majority of patients admitted require neuroleptic drug 
treatment. Extrapyramidal side effects are regularly seen 
amongst these patients. This study was designed to discover 
the incidence of parkinsonism, akathisia and dystonia amongst 
patients treated with neuroleptic drugs and what specific 
factors were responsible for these side effects. 
Relevent literature on this topic was reviewed and comparable 
studies done in America, Europe and South Africa are discussed. 
The study sample consisted of one hundred patients who were 
examined regularly over a two week period for signs of 
parkinsonism, akathisia, or dystonia which were rated 
quantitatively according to specific rating scales. Patient and 
drug variables were then analysed to assess what factors were 
responsible for these side effects. 
The incidence of drug-induced parkinsonism was 29%, akathisia 
35% and dystonia 20%. Combinations of these three syndromes 
were observed resulting in an overall incidence of 47%. 
High potency drugs such as haloperidol and trifluoperazine were 
responsible for a large percentage of all the side effects, 
while of the low potency drugs, thioridazine produced less side 
effects than chlorpromazine. Oral drugs combined with 
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intramuscular depot drugs resulted in a high incidence of side 
effects. 
The phase of treatment was clinically important with dys.tonia 
occurring more often within the first three days of treatment, 
akathisia within ten days and parkinsonism after ten to 
fourteen days. 
other factors that were studied included the patients age, sex 
and prior history of neuroleptic-induced neurological side 
effects. Due to the predominantly young patient population in 
this study, the mean age of those patients who developed 
parkinsonism was 26,7 years, akathisia 27,5 years and dystonia 
25,8 years. These side effects were seen more commonly in 
males than in females. Of the 27 patients in this study who 
had a prior history of neurological side effects , 15 (56%) 
developed simila~ side effects following re-exposure to 
neuroleptic drugs. 
Conclusions derived from this study include the need for 
clinicians to select the correct type and dose of neuroleptic 
for individual patients in order to minimise the development of 
neurological side effects. Accurate, early diagnosis of side 
effects by regular examination of patients is necessary for 
effective patient management. Clinicians should be made more 
aware of the side effects that can develop with the use of 
neuroleptic drugs and the effect these side effects have on 
patients. 
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Neuroleptic drugs have played an important part in the 
treatment of schizophrenia and many other psychiatric disorders 
for almost four decades. The introduction of chlorpromazine in 
the 1950' s revolutionized psychiatry and allowed many thousands 
of patients to be discharged from psychiatric hoqpitals. The 
developm.ent of depot preparations such as fluphenazine 
decanoate during the 1960's vastly improved the compliance of 
patients on long term drug treatment. A variety of neuroleptic 
drugs, with different chemical properties, have been introduced 
since then. Associated with the use of most of these drugs 
remains the problem of extrapyramidal side effects including 
parkinsonism, akathisia, dystonia and tardive dyskinesia. For 
the purposes of this study, only the acute neurological side 
effects are reviewed. 
Th~ clinical presentations of these drug-induced side effects 
are distinguished by certain neurological signs and symptoms. 
~arkinsonism is clinically similar to idiopathic parkinsons 
disease and is characterized by tremor, rigidity and 
bradykinesia. Akathisia involves an objective state of motor 
restlessness and a subjective feeling of unease with a constant 
desire to move. Dystonia involves involuntary muscle spasms of 
the face, eyes, tongue, neck or limbs. These neuroleptic-
induced side effects can be very distressing to patients and 
can lead to poor compliance with future treatment programmes. 
Review of the literature reveals that a number of stUdies have 
been conducted on drug-induced extrapyramidal side effects over 
the last thirty years. The incidence of these side effects is 
influenced by a number of variable factors which include the 
patients age, sex and individual vulnerability combined with 
the drug type, dose and phase of treatment (Sovner and DiMascio 
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1978 p.1021). This is further compounded by differences in 
methodological procedures, definitions and patient populations 
used in studies on this topic which makes comparison of the 
different studies difficult. 
In general, the studies done on patients receiving high and low 
potency drug combinations, such as chlorpromazine and 
fluphenazine, showed incidence rates for extrapyramidal side 
effects ranging from 37% (Decina et al 1992) to 61,9% (Ayd 1983 
p.86). Patients receiving only low potency drugs, such as 
chlorpromazine, showed a low (10,6%) incidence of side effects 
(Swett 1975), while patients treated with high potency drugs, 
such as haloperidol, were found to have incidence rates of 95 -
100% (Chiles 1978, Neborsky et al 1981). Studies looking 
specifically at the incidence of akathisia range from 19% 
(Barnes 1989) to 75% (Van Putten et al 1984). Dystonia 
incidence rates with high potency drugs, such as haloperidol, 
range from 31% (Addonizio and Alexopoulos 1988) to 94% (Boyer 
et al 1987), while with high and low potency combinations, such 
as chl0rpromazine and haloperidol, rates ranged from 10,1% 
(Swett 1975) to 20,9% (Stramek et al 1986). 
The age and sex of patients treated with neuroleptics 
influences the incidence of side effects with dystonia 
occurring more commonly in young individuals, particularly 
young males, while parkinsonism is seen more often in older age 
groups and akathisia in middle aged females (Ayd 1983 p.87). 
Individual vulnerability plays an important part in the 
development of extrapyramidal syndromes and a prior history of 
these side effects may predict an increased propensity for 
patients to develop this problem on re-exposure to neuroleptic 
drugs (Keepers and Casey 1991). 
The phase of treatment influences the clinical presentation of 
these side effects with dystonia likely to occur within the 
first few days of treatment while akathisia and parkinsonism 
occur over the next few weeks to months (Tarsy 1984). 
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There have been very few published studies done on drug-induced 
neurological side effects in South Africa. Holden et al (1984) 
conducted a survey of tardive dyskinesia amongst inpatients at 
Valkenberg hospital in Cape Town and found the incidence of 
this disorder to be 17%. Myslobodsky et al (1986) looked at 
parkinsonian symptoms in patients with tardive dyskinesia and 
found that 28 (57%) of the 49 patients in the study exhibited 
various parkinsonian symptoms which were attributed to the high 
doses of neuroleptics such as fluphenazine used in these 
patients. 
Acute extrapyramidal side effects have been reported to occur 
in up to 62% of psychiatric patients receiving neuroleptic 
treatment (Ayd 1983 p. 86) . This represents a significant 
clinical problem that warrants further study especially in 
South Africa where little research has been conducted on this 
subject. 
1 • 2 AIMS AND HYPOTHESES 
The aims of this study were to: 
1. Discover the incidence of parkinsonism, akathisia and 
dystonia in a group of hospitalized psychiatric patients 
receiving neuroleptic drug treatment. 
2. Examine the factors responsible for these specific 
extrapyramidal syndromes. 
3. Compare the results of this study with those found in 
similar stUdies reported in local and international 
literature. 
It was hypothesized that: 
1. There would be a relatively high incidence of 
parkinsonism, akathisia and dystonia amongst the 
patients in this study. 
2. The incidence of these side effects would be influenced 
by the type, dose and route of administration of the 
neuroleptic drugs used. 
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3. The age, sex and individual vulnerability of the 
patients would influence the presentation of these 
specific side effects. 
The results of this study could be used to assist clinicians in 




REVIEW OF LITERATURE 
Drug-induced extrapyramidal disorders have been studied by 
researchers from a number of different disciplines including 
psychiatry, neurology and clinical psychopharmacology. Review 
of the literature reveals that studies on this subject vary in 
methodological procedures, definitions and patientpopulations 
used. In reviewing the available information on parkinsonism, 
akathisia and dystonia, each syndrome is discussed under the 
following headings: 
1 Clinical Features 
2 Pathophysiology 
3 Epidemiology 
4 Factors Influencing Clinical Presentation 
4.1 Age 
4.2 Sex 
4.3 Drug Treatment 
4.4 Phase of Treatment 
2 . 1 PARKINSONISM 
2 . 1 . 1 Clinical Features 
Neuroleptic-induced parkinsonism is characterized by tremor, 
rigidity and bradykinesia which may be seen individually or in 
combination. The tremor is of moderate to high frequency and 
is seen during movement as well as rest. It is usuaL\.y seen in 
the hands and arms but in severe cases may involve the tongue, 
jaw and lower extremities (Sovner and DiMascio 1978 p.1023). 
Rigidity of the limbs can be elicited on passive movement and 
may be of the cogwheel type. Characteristic parkinsonian 
postural and gait abnormalities such as flexion of the trunk 
and limbs and shuffling propulsive or retropulsive gait can be 
seen in severe cases. 
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Bradykinesia is the earliest, most common sign observed and may 
consist of expressionless faces, slow movements, reduced 
armswing and soft, monotonous speech. 
2.1.2 pathophysiology 
The pyramidal and extrapyramidal systems are closely integrated 
and control strength and coordination of movement. The 
extrapyramidal system involves inputs from multiple brainstem 
and deep cortical nuclei that modulate pyramidal function. 
Pharmacologic studies have focused on the striatum (caudate and 
putamen) where there are high concentrations of dopamine and 
acetylcholine. Biochemical imbalance of the dopaminergic -
cholinergic system leads to abnormal, involuntary movement 
disorders. Neuroleptic drugs cause blockade of post synaptic 
dopamine receptors and this results in an underacti vi ty of 
striatal dopaminergic function (Marsden and Jenner 1980). The 
effect of this is extrapyramidal dysfunction and the clinical 
signs of parkinsonism. 
2.1.3 Epidemiology 
One study that is often quoted in the literature on this 
subject is that of Ayd (1961), where 15,4% of 3775 patients 
treated with neuroleptics developed parkinsonism. He continued 
his work over the next twenty years and gathered data on a 
further 5 000 patients treated with neuroleptics and discovered 
that 13,2% of this group developed drug-induced parkinsonism 
(Ayd 1983 p. 86) . These surveys involved large numbers of 
chronic patients treated with a range of different neuroleptics 
for periods of up to 5 years. Donlon and stenson (1976) 
studied 175 hospitalized schizophrenic patients on neuroleptic 
treatment and found that 28,8% developed parkinsonism. More 
recent studies by MCCreadie et al (1992) found that 27% of 146 
schizophrenic outpatients on neuroleptiic drugs showed signs of 
parkinsonism. Chakos et al (1992) studied 70 patients treated 
with fluphenazine over a ten week period and found that 34% of 
the sample developed parkinsonism. 
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The increasing incidence of parkinsonism in patients treated 
wi th neuroleptics over the last decade may be due to the 
increased use of high potency drugs and depot preparations. 
The use of more sensitive rating scales and more refined 
research criteria may have also influenced these results. 
2.1.4 Factors influencing clinical presentation 
2.1.4.1 Age 
Ayd (1961) reviewed 582 patients with drug-induced parkinsonism 
and compared the incidence of this syndrome with the age of the 
patients. There was an increased incidence in patients over 
the age of 40 years, reaching a peak in the 70 to 79 year age 
group which is similar to the age range for patients with 
idiopathic parkinsons disease. other researchers (Donlon and 
Stenson 1976, Chakos et al 1992) studying younger patient 
populations do not specify the age range of those patients who 
developed drug-induced parkinsonism. This syndrome is however 
commonly seen in young individuals treated with neuroleptics 
and thus age alone is not the only factor influencing the 
clinical presentation of parkinsonism (Sovner and DiMascio 1978 
p.1027). 
2.1.4.2 Sex 
Ayd (1961) reported that women were twice as likely to develop 
parkinsonism following neuroleptic drug treatment compared to 
men. This was based on data from 582 patients treated with 
seven different neuroleptic drugs. The doses used for males 
and females were however not equivalent. There have been no 
controlled studies done on the effect of gender on the 
incidence of acute extrapyramidal side effects. The sex of the 
patient i$ only one of the factors that influences the 
incidence of side effects such as parkinsonism (Marsden et al 
1975 p.231). 
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2.1.4.3 Drug Treatment 
The reported incidence of drug-induced parkinsonism varies from 
study to study and one of the factors responsible for this is 
the type of neuroleptic used. Studies done on patients 
receiving high and low potency drugs, such as chlorpromazine 
and fluphenazine, showed incidence rates for parkinsonism 
ranging from 13,2% (Ayd 1983 p. 86) to 27% (McCreadie et al 
1992) . Where high potency drugs, such as haloperidol or 
fluphenazine have been used, the incidence rates for 
parkinsonism range from 34% (Chakos et al 1992) to 40% (Binder 
and Levy 1981). This can be explained to some degree by the 
relatively higher anticholinergic properties of the low potency 
drugs such as chlorpromazine and thioridazine compared to the 
high potency drugs such as haloperidol and fluphenazine (Snyder 
et al 1974). The dose of neuroleptic used also appears to 
influence the incidence of these side effects with the middle 
dosage range of each drug having the highest incidence of 
extrapyramidal side effects (Sovner and DiMascio 1978 p.1026). 
2.1.4.4 Phase of treatment 
Signs of parkinsonism may begin within a few days of drug 
treatment with a gradual increase in incidence so that up to 
75% of cases appear by one month (Marsden et al 1975 p.230). 
The development of parkinsonism may be more rapid with severe 
signs developing over days following depot preparations such as 
fluphenazine decanoate (Ayd 1975). Sudden discontinuation of 
concurrent anticholinergic drug treatment may also lead to a 
recurrence of parkinsonism features in predisposed individuals 
(Manos et al 1981). 
9 
2 • 2 AKATHISIA 
2.2.1 Clinical Features 
Akathisia is a movement disorder with two major components : 
an objective state of motor restlessness and a subjective 
feeling of unease with a desire to move. The motor component 
is characterized by an inability to stand still, purposeless 
limb movements, pacing or shifting from foot to foot. The 
restlessness is not localized to any part of the body and may 
range from nonspecific fidgety movements to a state of constant 
movement. The subjective state of restlessness is usually 
described as a feeling of uneasiness or tension and can be very 
distressing to patients. They may also suffer from initial 
insomnia because they cannot lie motionless in bed long enough 
to fall asleep (Ratey and Salzman 1984). 
2.2.2 Pathophysiology 
Akathisia occurs in some individuals following treatment with 
neuroleptic drugs. The exact pathogenesis is not known, but 
~he most plausible current hypothesis put forward by Marsden 
and Jenner (1980) implicates competitive blockade of 
mesocortical post synaptic dopamine receptors by neuroleptic 
drugs. Blockade of dopamine receptors in the striatum and 
mesolimbic areas such as the nucleus accumbens produces 
inhibition of locomotion, while the reverse occurs with 
blockade of mesocortical dopamine systems (Marsden and Jenner 
1980). Further research is required to confirm this 
hypothesis. 
2.2.3 Epidemiology 
Van Putten and Marder (1986) state that akathisia is under-
recognized and that this has been due to the lack of clear 
operational definitions. The diagnosis of akathisia has tended 
to rely on questioning about a patient's inner restlessness, 
but reliance on a pa~ients subjective feelings alone does not 
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lead to reliable diagnosis. Barnes (1989) developed a rating 
scale for drug-induced akathisia which incorporates both 
subjective and objective features and appears a more reliable 
method of diagnosing this disorder. 
Estimates on the incidence of akathisia vary a great deal. 
Gibb and Lees (1986) believe that as many as 50% of patients on 
chronic neuroleptic therapy could have mild akathisia. Ratey 
and Salzman (1984) report that 20-45% of patients on 
neuroleptic treatment have definite signs and symptoms of 
akathisia. In a prospective study of acute inpatient 
admissions by Braude et al (1983), the incidence of akathisia 
was found to be 25%. Figures as high as 75% have been reported 
(Van Putten et al 1984) with the use of drugs such as 
haloperidol. Marsden et al (1975 p. 234) believe that incidence 
figures of 20% are generally accepted by researchers in this 
field. 
2.2.4 Factors influencing clinical presentation 
2.2.4.1 Age 
Review of the literature reveals that there is some variation 
in the age of patients who develop akathisia following 
neuroleptic drug treatment. Ayd (1961) noted that akathisia 
can occur at any age, but is more prevalent amongst middle aged 
patients. Marsden et al (1975 p.234) report that the incidenoe 
of akathisia is fairly uniform between the ages of 12 and 65 
years. Ratey and Salzman (1984) believe that akathisia is more 
common in the elderly with a peak incidence in the eighth 
decade. Further studies on the effect of age on the incidence 
of akathisia are needed to clarify this issue. 
2.2.4.2 Sex 
The effect of gender on the incidence of akathisia has not been 
clearly demonstrated. Studies done on patients with akathisia 
(Braude et al 1983, Gibb and Lees 1986) do not comment on the 
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incidence of akathisia according to patients sex. Akathisia 
has been reported to occur more commonly in female patients 
than in males following neuroleptic drug treatment (Ayd 1961). 
This survey did not however control for the dose of neuroleptic 
used. Marsden et al (1975 p.234) feels that female patients 
receive somewhat higher doses of neuroleptics than males and 
this may influence the incidence rates. Controlled studies 
would be needed to answer this question. 
2.2.4.3 Drug treatment 
Akathisia is probably the most common neurological side effect 
that develops following treatment with neuroleptic drugs 
(Marsden et al 1975 p.234). The incidence of akathisia does 
however vary according to the potency of drug used. Van Putt en 
et al (1984) studied the incidence of akathisia in two 
populations of newly admitted schizophrenic patients: one group 
was treated with haloperidol and the other group received 
thiothixene hydrochloride at fixed doses. 75% of the patients 
who received haloperidol developed akathisia by the seventh day 
compared to only 46% of those patients who received 
thiothixene. Low potency drugs such as thioridazine are less 
likely to produce akathisia than the high potency drugs such as 
haloperidol, while depot preparations such as fluphenazine 
decanoate are not more liable to evoke akathisia than other 
potent oral drugs (Ayd 1975). The dose of drug used is also an 
important factor and although there is no direct linear 
relationship, lower doses of neuroleptics produce less 
akathisia. 
2.2.4.4 Phase of treatment 
Ayd (1961) noted that akathisia generally precedes drug-induced 
parkinsonism in time of onset and that the incidence of 
akathisia increases with time so that about 50% of such 
reactions occur within the first month of treatment with oral 
neuroleptics. Following a dose of intramuscular fluphenazine 
decanoate, 90% of the cases of akathisia develop within one to 
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four days (Ayd 1975). 
Braude et al (1983) studied 104 patients on neuroleptic drug 
treatment and found that 26 (25%) developed akathisia. All of 
these patients showed signs of akathisia after large increases 
in drug dosage which usually occurred in the first 10 days of 
treatment. Akathisia can however develop within hours of 
starting treatment as was shown by Van Putt en et al (1984) 
where patients started on oral haloperidol were observed to 
have clinical signs of akathisia within six hours of the first 
dose. 
2 • 3 DYSTONIA 
2.3.1 Clinical Features 
The typical presentation of dystonia is one of intermittent or 
sustained muscular spasms leading to abnormal postures or 
facial movements. The clinical presentation depends on which 
muscle groupp are involved; when the muscles ot the head and 
face are involved, facial grimacing, tics, tongue protrusion, 
forced jaw opening, distortions of the lips, occulogyric crises 
or other aversive eye movements may occur. Involvement of the 
neck muscles produces torticollis or retrocollis and 
involvement of the pharyngeal muscles can produce dysphasia or 
respiratory distress while involvement of the trunk or limbs 
leads to abnormal postures and limb movements (Tarsy 1984). 
2.3.2 Pathophysiology 
The physiology of dystonic reactions has been studied by 
Marsden and Jenner (1980) who proposed the following process. 
Neuroleptic drugs cause a dopamine blockade which leads to 
compensatory changes in pre and post synaptic dopamine 
receptors. As the neuroleptic concentration decreases after 
~cute administration, super-sensitive post synaptic dopamine 
receptors are left exposed. Any dopamine that is then release 
13 
provokes an enhanced response at these receptors. The clinical 
resul t of this complex process is seen as acute dystonic 
reactions. Why only some individuals develop these side 
effects has not been clearly demonstrated and may represent an 
idiosyncratic reaction or a doge dependent condition (Marsden 
and Jenner 1980). 
2.3.3 Epidemiology 
The incidence of dystonia has been well documented by many 
researchers. In the early 1960's Ayd (1961) noted tnat 2,3% of 
3775 patients developed dystonia following phenothiazine 
treatment. A study by Swett (1975) of 1152 psychiatric 
patients treated with neuroleptic drugs, revealed that 10,1% 
developed dystonia. A further study by Ayd (1983 p.86) found 
that 11,9% of the patients developed dystonia, while more 
recent studies by Khanna et al (1992) found incidence rates for 
dystonia of 20%. Figures as high as 94% have been reported in 
patients treated with haloperidol (Boyer et al 1987). There is 
a consensus of opinion that the increased incidence figures 
since the 1960's are due to the increasing use of high potency 
drugs and depot neuroleptics. 
2.3.4 Factors influencing clinical presentation 
2.3.4.1 Age 
studies over the past thirty years have confirmed that the 
incidence of dystonia is higher in younger individuals. A 
study of extrapyramid~l reactions in adolescents treated with 
high potency antipsychotics by Chiles (1978) revealed that 7 
(64%) of 11 patients aged 13 - 18 years developed dystonic 
reactions. Addonizio and Alexopoulos (1~88) compared drug 
induced dystonia in young and elderly patients and found that 
31% of the young patients (mean age 26 years) developed 
dystonia compared to only 2% of the elderly patients (mean age 
69 years). This study controlled for the type and dose of 
drugs used in the two groups. 
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Why neuroleptic induced dystonia occurs less frequently in the 
elderly remains unclear. It is possible that age related 
degeneration of the striatum may diminish dopaminergic acti vi ty 
which may decrease the likelihood of dystonia (Addonizio and 
Alexopoulos 1988). 
2.3.4.2 Sex 
Ayd's (1983 p.87) surveys of extrapyramidal side effects found 
that dystonic reactions were twice as comItJon in males than in 
females. Arana et al (1988) reviewed the available literature 
on acute dystonias and found that the incidence of dystonia is 
higher in male patients esp~cially younger men. One has to 
also consider that young, hostile male patients frequently 
receive higher doses of neuroleptics which may influence the 
incidence figures in this group of patients (Chakos et al 
1992). 
2.3.4.3 Drug treatment 
swett (1975) investigated the relative incidence of dystonia 
according to type of neuroleptic used and found the incidence 
with haloperidol to be 16%, trifluoperazine 8,2%, 
chlorpromazine 3,5% and thioridazine 0,6%. Arana et al (1988) 
reviewed a number of studies on dystonia and found that the 
incidence of dystonia in studies using high and low potency 
neurolpetics was 14,8% while in studies using only high poten9Y 
neuroleptics, this figure was 51,2%. Boyer et al (1987) found 
the incidence of dystonia in a group of young adults treated 
with haloperidol to be 94%. These findings indicate that the 
incidence of dystonia with different neuroleptics seems to 
parallel the differential incidence of drug-induced 
parkinsonism with high potency drugs causing a higher incidence 
of side effects than the low potency drugs (Goetz and Klawans 
1981) . 
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The dose of drug used is also important with high doses or 
rapid increases in dose leading to a higher incidence of 
dystonia. Swett (1975) found that doses of chlorpromazine 
greater than 300mg per day caused significantly more dystonic 
episodes than if doses of 100mg per day or less were used. 
2.3.4.4 Phase of treatment 
Dystonic reactions usually begin within hours of starting 
neuroleptic treatment with the majority occurring within the 
first few days. Marsden et al (1975 p.232) report that 
approximately 50% of dystonic reactions will occur within forty 
eight hours and up to 90% within five days of starting drug 
treatment. They may either remit or fluctuate spontaneously 
over several hours but often reappear on increasing the dose of 
neuroleptic. Depot preparations given intramuscularly may 
produce acute dystonias within 12 24 hours of each 
administration (Ayd 1975). New dystonic reactions are rare 
after the first few weeks of treatment and are not often seen 
in chronic patients on maintenance treatment. 
2.4 COMBINED NEUROLOGICAL SYNDROMES 
Dystonia, parkinsonism and akathisia can develop as individual 
side effects in the absence of the others, but all of the 
possible combinations of these reactions are commonly seen. In 
a study of 70 patients receiving fluphenazine, Chakos et al 
(1992) found that 38% of the patients had one form of acute 
extrapyramidal side effect while 21% had two forms and 3% all 
three forms of side effect. 
study of 175 patients, 12 
parkinsonism and dystonia. 
In Donlon and stenson's (1976) 
(7%) showed 
Patients 
combined signs of 
may develop the 
neurological side effects simultaneously or at different times 
during their treatment with neuroleptics. 
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2.5 PRIOR HISTORY OF NEUROLOGICAL SIDE EFFECTS 
Susceptibility to extrapyramidal side effects varies widely 
amongst patients treated with neuroleptic drugs. wi thout 
reliable methods of predicting these side effects, many 
patients are unnecessarily treated with prophylactic 
anticholineJ;:"gic medications. In an attempt to predict future 
vulnerability to these side effects, Keepers and Casey (1991) 
studied 62 patients who had a prior history of extrapyramidal 
side effects and found tnat 84% of these patients develope4 
side effects on re-exposure to neuroleptic drugs. This result 
supports the hypothesis that patients with · a history of 
extrapyramidal syndromes are at greater risk for future side 
effects due to their individual susceptibility. possible 
reasons for this include variations in drug metabolism, 
neurotransmitters, micro-anatomy of the basal ganglia or that 
neuroleptic exposure produces a reverse tolerance to 
extrapyramidal syndromes (Keepers and Casey 1991). Further 
research is need to clarify this problem. 
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CHAPTER 3 
PATIENTS AND "ETHODS 
3.1 COMPOSITION OF STUDY SAMPLE 
This was a prospective study conducted over a three month 
period at Fort Napier Hospital. The study sample consisted of 
all patients admitted to the hospital who met the following 
criteria: 
1) patients who clinically required neuroleptic drug 
treatment 
2) patients who had not been treated with depot neuroleptic 
preparations in the month prior to admission 
3) patients who had not been on regular oral antipsychotic 
treatment in the two weeks prior to admission 
4) patients who did not require anticholinergic, 
antidepressant, anticonvulsant or anxiolytic drugs in 
combination with the prescribed neuroleptic drug 
treatment 
5) patients wi th no clinical signs of any other 
neurological disorder involving the extrapyramidal 
system 
6) patients with no clinically significant extrapyramidal 
side effects on qdmission 
All patients in the study sample were over sixteen years of age 
and included both males and females. 
3 . 2 CONSENT PROCEDURES 
On admission each patient was interviewed and those who met the 
study criteria were asked to give written consent (Appendix A) 
for inclusion in the study. 
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Informed consent was obtained where possible by explanation of 
the procedure to the patient by a Zulu speaking staff member. 
This included the reasons for the study, the examination 
procedures and the freedom to withdraw from the study at any 
time without prejudice to their further management. 
If the patient was unable to give written consent, attempts 
were made to obtain consent from accompanying relatives. If 
this was not possible consent was obtained from the medical 
superintendent. 
3.3 RATING SCALES 
To objectively measure the different extrapyramidal syndromes, 
sp,ecific rating scales were used. Each patient was examined by 
the author to avoid any inten-rater variability. 
3.3.1 Parkinsonism 
In assessment of neuroleptic induced parkinsonism, the rating 
scale for extrapyramidal side effects (Appendix B) by Simpson 
and Angus (l970) was used. This rating scale includes the 
following ten items: gait, arm dropping, shoulder shaking, 
elbow rigidity, wrist rigidity, leg pendulousness, head 
dropping, glabella tap, tremor, salivation. 
Each item is rated from 0 to 4, where 0 is normal and 4 the 
extreme of that particular condition. Each patient was 
examined and a net score obtained by adding the scores of the 
ten items and dividing by ten. This was then recorded as 
follows: 0 - 0,9 norltJ,al, 1 - 1,9 mild parkinsonism, 2 - 2,9 
moderate parkinsonism, 3 
extreme parkinsonism. 
3,9 marked parkinsonism and 4 
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3.3.2 Akathisia 
The rating scale for drug-induced akathisia (Appendix C) by 
Barnes (1989) was used for the assessment of akathisia. using 
this protocol each patient was examined for objective signs of 
restlessness while seated, standing and involved in activities. 
The individuals were also interviewed and questioned about 
subjecti ve feelings of restlessness. These features were rated 
according to a global clinical assessment of akathisia where 0 
indicated no sign of akathisia and 5 severe akathisia. 
3.3.3 Dystonia 
For this condition each patient was examined and questioned 
about any dystonic movements since starting treatment. This 
was combined with nursing observation reports on the patient 
since admission. If dystonic movements had occurred, they were 
recorded according to type (body part involved) and the day on 
which they started. Dystonia was recorded as either being 
present or absent and not graded according to severity. This 
information was recorded on a data sheet (Appendix D). 
3.4 DATA COLLECTION PROCEDURES 
Each patient was interviewed and information obtained on prior 
psychiatric treatment with neuroleptic drugs, any prior history 
of extrapyramidal syndromes and any present neurological side 
effects. A physical examination was performed on each patient 
looking particularly for the neurological features described in 
the rating scales. These examinations were done on admission 
and on day 5, 10 and 14 where possible. Examinations after day 
14 were not always possible as a large percentage of the 
patients were discharged from hospital after 2 to 3 weeks of 
treatment. 
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The scores obtained from each examination were recorded on a 
composite data sheet (Appendix E). The patients current drug 
treatment was recorded including drug type, dose and route of 
administration. The total daily drug dose was converted to 
chlorpromazine equivalents (Davis 1976). 
3.5 STATISTICAL ANALYSIS 
The statistical analysis was conducted under the direction of 
Miss E Gouws at the Institute of Biostatistics of the medical 
research council Durban. Descriptive statistics were used to 
analyse the specific variables influencing the extrapyramidal 
syndromes and where relevant the Chi Square technique was used 
to determine statistical significance. Duncans multiple range 
test was used to compare the effect of the various drugs on the 




4 • 1 SAMPLE DETAILS 
404 patients were admitted to the admission wards of Fort 
Napier hospital over the three month study period. Of this 
number, 100 patients met the criteria for inclusion into the 
study. This group consisted of 67 males and 33 females ranging 
in age from 17 to 65 years with a mean age of 29,4 years. A 
breakdown by age and sex is shown in TABLE I from which it can 
be seen that 52 (52%) of the patients were aged 20 to 29 years. 
This group consisted of 39 males and 13 females while 31 (31%) 
of the patients were aged 30 to 39 years and this included 18 
males and 13 females. There were only 6 patients aged less than 
20 years and 3 patients ag~d over 50 years. 
TABLE I 
Distributiofl of patients according to age and sex. 
AGE GROUP NUMBER OF PATIENTS 
(YEARS) 
MALE FEMALE TOTAL 
< 20 5 1 6 
20 - 29 39 13 52 
30 - 39 18 13 31 
40 - 49 3 5 8 
50 - 59 1 1 2 
60 - 69 1 0 1 
TOTAL 67 33 100 
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4.2 NEUROLEPTIC DRUGS USED 
The types of drugs and dosages used in this study are shown in 
TABLE 11. 
TABLE 11 
Drug types and dosage 
DRUG TYPE NO OF CASES DOSE RANGE MEAN DOSE 
TREATED (mg/day CPZ (mg/day 
equiv) CPZ equiv) 
Thioridazine 11 50 - 600 345 
Thioridazine + IM drug 3 350 - 700 583 
Chlorpromazine 34 200 - 1200 531 
Chlorpromazine + IM drug 28 250 - 1000 630 
Trifluoperazine 5 300 - 600 490 
Trifluoperazin.e + IM drug 3 300 - 700 500 
Haloperidol 11 225 - 2000 1157 
Haloperidol + IM drug 3 350 - 2100 1183 
Zuclopenthixol Decanoate IM 2 100 100 
(IM - IntraMuscular) 
11 patients were treated with thioridazine, mean dose 345 
mg/day, 34 patients with chlorpromazine, mean dose 531 mg/day, 
5 patients with trifluoperazine, mean dose 490 mg/day and 11 
patients with haloperidol, mean dose 1157 mg/ day. 2 patients 
were treated with Zuclopenthixol depot alone, mean dose 
100mg/day. (Doses converted to chlorpromazine equivalents.) 
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Chlorpromazine was prescribed more often than any other drug in 
this study with 34 patients receiving chlorpromazine alone and 
28 patients receiving combinations of chlorpromazine and 
intramuscular drug. 
The combinations of oral and intramuscular drugs used are shown 
in TABLE Ill. 
TABLE III 



















NUMBER OF CASES 
COMBINED WITH 
NO ORAL THIORID CPZ TFP 
DRUG AlINE 
0 1 8 2 
0 0 3 0 
2 0 2 0 
0 2 3 1 
0 0 12 0 













The intramuscular drugs used included zuclopenthixol acetate, 
zuclopenthixol decanoate, flupenthixol decanoate and 
fluphenazine decanoate combined with thioridazine, 
chlorpromazine, trifluoperazine or haloperidol. Analysis of 
this data was not undertaken as most of the subgroup samples 
were too small for statistical analysis and it was not possible 
to control for many of the variable factors related to the use 
of these drugs. 
TABLE IV 
Drugs used according to patient sex 
DRUG TYPE NUMBER OF % OF NUMBER OF % OF 
MALE MALES IN FEMALE FEMALES 
CASES STUDY CASES IN STUDY 
TREATED TREATED 
Thioridazine 7 11 4 12 
Thioridazine & IM drug 2 3 1 3 
Chlorpromazine 18 27 16 49 
Chlorpromazine & IM drug 18 27 la 30 
Trifluoperazine 3 4 2 6 
Trifluoperazine & IM drug 3 4 0 0 
Haloperidol 11 16 0 0 
Haloperidol & IM drug 3 5' 0 0 
Zuclopenthixol Decanoate 2 3 0 0 
IM 
Total 67 100 33 100 
IM - In ( traMuscular) 
A breakdown of the drugs used according to the sex of the 
patients is shown in TABLE IV. Of note is that 16 (49%) of the 
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females in the study were treated with chlorpromazine compared 
to 18 (27%) of the males, while 11 (16%) of the males were 
treated with haloperidol and no females in the study received 
haloperidol. 7 (11%) of the males were treated with 
thioridazine compared to 4 (12%) of the females in the study. 
3 (4%) of the males were treated with trifluoperazine compared 
to 2 (6%) of the females in the study. 
received zuclophenthixol decanoate alone. 
4 • 3 PARKINSONISM 
4.3.1 Incidence 
Only 2 (3%) males 
with reference to TABLE V it can be seen that of the 100 
patients in the study, 21 (21%) developed mild parkinsonism, 5 
(5%) moderate and 3 (3%) marked parkinsonism. This gives a 
total of 29 (29%) patients with drug-induced parkinsonism. 
There were no cases of extreme parkinsonism while 71 (71%) 
patients had no clihically significant signs of parkinsonism. 
TABLE V 
Severity of parkinsonism 
PARKINSONISM RATING SCALE NUMBER OF CASES TOTAL 
SEVERITY SCORE MALE FEMALE 
Extreme 4 0 0 0 
Marked 3+ 2 1 3 
. Moderate 2+ 3 2 5 
Mild 1+ 19 2 21 
Nil 0+ 43 28 71 
67 33 100 
26 
4.3.2 Age 
The age range for the 29 cases of parkinsonism was 18 to 38 
years with a mean age of 26, 7 years. Breakdown by sex is shown 
in TABLE VI where it can be seen that the mean age for the 
males was 27,1 years and females 24,4 years. 
TABLE VI 
Age of parkinsonism cases 
SEX NUMBER OF AGE RANGE MEAN AGE 
CASES (YEARS) (YEARS) 
Ml\LE 24 18 - 38 27,1 
FEMALE 5 19 - 31 24,4 
TOTAL 29 18 - 38 26,7 
4.3.3 Sex 
Of the 67 males in the study, 24 (35,8%) developeQ signs of 
parkinsonism while only 5 of the 33 females (15,2%) showed 
these signs. 
4.3.4 Drug treatment 
The incidence of parkinsonism according to type of drug used is 
shown in TABLE VII. There were no cases of parkinsonism 
observed with the use of thioridazine alone or in combination 
wi th an intramuscular drug. 12% of the patients developed 
parkinsonism when treated with chlorpromazine, while 
these signs after recelvlng chlorpromazine 




parkinsonism was observed with the use of trifluoperazine and 
haloperidol especially when combined with an intramuscular 
drug. There were no cases of parkinsonism seen when 
zuclopenthixol decanoate was used alone. 
TABLE VII 
Parkinsonism according to drug type 
NUMBER OF PARKINSONISM 
DRUG TYPE CASES 
TREATED NUMBER OF 
CASES % 
Thioridazine 11 0 0 
Thioridazine & IM drug 3 0 0 
Chlorpromazine 34 4 12 
Chlorpromazine & IM drug 28 7 25 
Trifluroperazine 5 3 60 
~rifluroperazine & IM drug 3 3 100 
Haloperidol 11 9 82 
Haloperidol & IM drug 3 3 100 
Zuclopenthixol Decanoate 2 0 0 
IM 
(IM IntraMuscular) 
4 . 3 . 5 Phase of treatment 
Clinical examinations were conducted on day 1, 5, 10 and 14 
where possible. Parkinsonism scores increased steadily from 
day 10 onwards with the majority of significant scores obtained 




As can be seen in TABLE VIII, of the 100 cases in the study 24 
showed mild akathisia, 10 moderate and 1 marked akathisia. 
This is a total of 35 cases (35% ) with clinical signs of 
akathisia. 18 cases had questionable signs of akathisia and 47 
no signs of akathisia. 
TABLE VIII 
severity of akathisia 
AKATHISIA RATING SCALE NUMBER OF CASES TOTAL 
SEVERITY SCORE 
MALE FEMALE 
Severe 5 0 0 0 
Marked 4 1 0 1 
Moderate 3 7 3 10 
Mild 2 16 8 24 
Questionable 1 9 9 18 
Absent 0 34 13 47 
67 33 100 
4.4.2 Age 
The age range for the 35 cases of akathisia was 19 to 50 years 
with a mean age of 27,5 years. Breakdown by sex is shown in 
TABLE IX where it can be seen that the mean age of the male 




Age of akathisia cases 
SEX NUMBER OF AGE RANGE MEAN AGE 
CASES (YEARS) (YEARS) 
MALE 24 19 - 40 26,3 
FEMALE 11 19 - 50 30 
TOTAL 35 19 - 50 27,5 
4.4.3 Sex 
Of the 67 males in the study, 24 (35 I 8%) developed signs of 
akathisia while 11 of the 33 females (33,3%) showed these 
signs. 
4.4.4 Drug treatment 
The incidence of akathisia according to type of drug used is 
shown in TABLE X. No cases of akathisia were observed with the 
use of thioridazine alone. 10 (29%) o·f the 34 cases treated 
with chlorpromazine developed akathisia while 11 (39%) of the 
28 patients treated with chlorpromazine combined with an 
intramuscular drug developed akathisia. 7 (64%) of the 11 
patients treated with haloperidol developed akathisia. 
Phase of treatment 
Clinical examinations were conducted on day 1, 5, 10 and 14 
where possible. Scores for akathisia were on average highest 
by day 10 of treatment and by day 14 there was some reduction 
in the scores. 
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TABLE X 
Akathisia according to drug type 
NUMBER OF AKATHISIA 
DRUG TYPE CASES 
TREATED NUMBER OF 
CASES ~ 0 
Thioridazine 11 0 0 
Thioridazine & IM drug 3 1 33 
Chlorpromazine 34 10 29 
Chlorpromazine & IM drug 28 11 39 
Trifluroperazine 5 2 40 
Trifluroperazine & IM drug 3 1 33 
Haloperidol 11 7 64 
Haloperidol & IM drug 3 2 66 
Zuclopenthixol Decanoate 2 1 50 
IM 
IM - IntraMuscular 
4.5 DYSTONIA 
4.5.1 Incidence 
Of the 100 cases in the study 20 (20%) developed dystonic 
reactions. A breakdown of the types of dystonia observed is 
shown in TABLE XI and from this it can be s~en that the 
majority (12) involved the tongue. 
4.5.2 Age 
The age range for the 29 cases of dystonia was 18 to 49 years 
with a mean age of 25,8 years. Breakdown by sex is shown in 
TABLE XII where it can be seen that the mean age of the male 




TYPE OF DYSTONIA NUMBER OF CASES TOTAL 
MALE FEMALE 
Tongue 10 2 12 
Mouth 1 0 1 
Jaw 2 0 2 
Neck 1 1 2 
Mouth and Tongue 0 2 2 
occulogyric 0 1 1 
TOTAL 14 6 20 
TABLE XII 
Age of dystonia cases 
SEX NUMBER OF AGE RANGE MEAN AGE 
CASES (YEARS) (YEARS) 
MALE 14 18 - 34 25,1 
FEMALE 6 19 - 49 27,3 
TOTAL 20 18 - 49 25,8 
4.5.3 Sex 
Of the 67 males in the study, 14 (20,8%) developed dystonic 
reactions while 6 (18,2%) of the 33 females developed this side 
effect. The different types of dystonias according to patient 
sex are shown in TABLE XI. Of note is that 10 (71%) of the 14 
male patients had dystonias involving the tongue. 
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4.5.4 Drug treatment 
The incidence of dystonia according to type of drug used is 
shown in TABLE XIII. No cases of dystonia were observed with 
the use of thioridazine alone or in combination with an 
intramuscular drug. 
4 (12%) of the 34 patients treated with chlorpromazine 
developed dystonic reactions while 9 (32%) of the 28 patients 
treated with chlorpromazine and intramuscular drug developed 
dystonic reactions. 5 (45%) of the 11 cases treated with 
haloperidol developed dystonias. 
TABLE XIII 
Dystonia according to drug type 
NUMBER OF DYSTONIA 
DRUG TYPE CASES 
TREATED NUMBER OF 
CASES ~ 0 
Thioridazine 11 0 0 
Thioridazine & IM drug 3 0 0 
Chlorpromazine 34 4 12 
Chlorpromazine & IM drug 28 9 32 
Trifluroperazine 5 2 40 
Trifluroperazine & IM drug 3 0 0 
Haloperidol 11 5 45 
Haloperidol & IM drug 3 0 0 
Zuclopenthixol Decanoate 2 0 0 
IM 
( IM - IntraMu scular) 
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4.5.5 Phase of treatment 
17 (85%) of the 20 cases of dystonia occurred within the first 
72 hours of treatment while the remainder occured within 5 
days. 
4.6 COMBINED NEUROLOGICAL SYNDROMES 
There were 29 (29%) cases of parkinsonism, 35 (35%) cases of 
akathisia and 20 (20%) cases of dystonia in this study. These 
figures do not however reflect those patients who developed 
more than one neurological syndrome. with reference to TABLE 
XIV it can be seen that there were various combinations of the 
three syndromes including 9 (9%) patients with combined 
parkinsonism, akathisia and dystonia, 11 (11%) with 
parkinsonism and akathisia, 4(4%) with parkinsonism and 
dystonia and 4 (4%) with akathisia and dystonia. 
TABLE XIV 
Combined Neurological syndromes 
NUMBER OF CASES S Y N D ROM E S 
PARKINSONISM AKATHISIA DYSTONIA 
53 - - -
5 j - -
11 - j -
3 - - j 
11 j j -
4 j - j 
4 - j j 
9 j j j 




As can be seen in TABLE XV, 53 (53%) of the patients did not 
develop clinically significant extrapyramidal syndromes while 
the 47 (47%) who did consisted of 19 (19%) with one syndrome, 
19 (19%) with two syndromes and 9 (9%) witl1 three syndromes. 
TABLE XV 
Number of neurological syndromes 
NUMBER OF SYNDROMES NUMBER OF CASES PERCENTAGE 
0 53 53 
1 19 19 
2 19 19 
3 9 9 
TOTAL 100 100 
4.7 PRIOR HISTORY OF NEUROLOGICAL SIDE EFFECTS 
Of the 100 patients in the study, 46 gave a history of prior 
treatment with neuroleptic drugs. Of this group 27 (59%) had 
developed neurological side effects as a result of their 
treatment. Of these 27 patients, 15 (56%) developed side 
effects in this study. These included various combinations of 
neurological syndromes with no one type predbminating. 
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CHAPTER 5 
DISCUSSION OF RESULTS 
5.1 SAMPLE DETAILS 
404 patients were admitted to Fort Napier hospital over the 
three month study period. This included 302 males and 102 
females of which 67 males and 33 females were included in the 
study. These patients were plainly young adults with 52% being 
aged 20 - 29 years and 31% aged 30 - 39 years. The mean age of 
the male patients was 28,4 years compared to 31,3 years for the 
females. This study sample reflects the predominantly young 
patient population treated at this hospital. 
Review of the literature shows that besides some large surveys 
(swett 1975, Ayd 1983 p. 86), most of the studies done on 
extrapyramidal side effects involved small samples of young to 
middle aged patients (McEvoy 1983, Aranaet al 1988). 
5.2 NEUROLEPTIC DRUGS USED 
Two types of low potency drugs, thioridazine and 
chlorpromazine, and two high potency drugs, trifluoperazine and 
haloperidol, were used alone or in combination wi th 
intramuscular drugs. To allow comparison between drugs, the 
mean daily dose of each drug was converted to chlorpromazine 
equivalents. with reference to TABLE II (page 22) it can be 
seen that there were differences between the mean daily dose of 
each drug, with haloperidol being used in much higher doses 
(l157mg/day, chlorpromazine equivalents) compared to 
thioridazine (345mg/day, chlorpromazine equivalents). 
The number of patients treated with each drug was unequal with 
varying combinations of oral and intramuscular drugs being 
used. Chlorpromazine was used more often than any other oral 
drug. There were also differences in the type of drug used to 
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treat male and female patients as can be seen in TABLE IV (Page 
24) where 16% of the males in the study were treated with 
haloperidol while no females received haloperidol. These 
differences may reflect the prescribing habits of the 
clinicians involved or as Chakos et al (1992) notes that 
agitated young male patients often receive larger doses of 
higher potency drugs than do females. Ideally the type and 
dose of neuroleptics used in a study of extrapyramidal side 
effects should be controlled. This is not always possible for 
ethical reasons and only a few such studies are reported in the 
literature (Garver et al 1976, Van Putten et al 1984). Other 
stUdies have attempted to compare the incidence of neurological 
side eff~cts with varying doses of one neuroleptic drug 
(Levinson et al 1990). There is however a definite need for 
more controlled studies on the incidence of extrapyramidal side 
effects resulting from the use of neuroleptic drugs. 
5.3 PARKINSONISM 
5.3.1 Incidence 
The incidence of parkinsonism in this study was 29% which 
compares favourably with other studies on this subject (Donlon 
and Stenson 1976, McCreadie et al 1992). Previous published 
studies (Sheppard and Merlis 1967) indicate that between 20 and 
40 percent of patients treated with neuroleptics develop 
parkinsonism. 
5.3.2 Age 
Ayd (1961) found that the incidence of parkinsonism was higher 
in patients over the age of 40 years though in this study the 
mean age of the 29 patients who developed parkinsonism was 26,7 
years. This may be a consequence of the predominantly young 
patient popUlation in this study, given that 89% of the 
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patients were less than 40 years of age, though it is possible 
that parkinsonism is seen more commonly in young patients than 
has previously been reported. A larger study with a wider age 
range of patients would be needed to clarify this. 
5.3.3 Sex 
24 (35,8%) of the male patients in the study developed 
parkinsonism compared to 5 (15,2%) of the female patients. 
This difference is statistically significant (p = 0,032), but 
may reflect the different neuroleptics used in the treatment of 
males compared to the females with male patients receiving more 
high potency drugs than the female patients. The results of 
this study differ from the reports in the literature (Ayd 1961) 
that females more commonly develop parkinsonism. Further 
research is required to clarify this point using equal numbers 
of males and females treated with a fixed dose of one drug. 
5.3.4 Drug treatment 
The parkinsonism scores for patients treated with haloperidol 
and trifluoperazine were significantly higher than those of 
patients treated with chlorpromazine and thioridazine (p = 
0,0001). This compares favourably with studies done elsewhere 
(Snyder et al 1974). Thioridazine in particular is unlikely to 
cause significant signs of parkinsonism as was shown in this 
study. There were however differences in the mean daily dose 
of neuroleptic used, with haloperidol being used in much higher 
doses than thioridazine. The trends observed in this study are 
however similar to those found in other studies (Sovner and 
DiMascio 1978 p.1025). 
5.3.5 Phase of treatment 
Signs of parkinsonism were observed to increase over the two 
week study period with most of the clinically significant cases 
recorded by day 14. it is likely that if the study period had 
38 
been longer more patients would have shown signs of 
parkinsonism. This is supported by other studies that describe 
the development of parkinsonism over weeks to months (Marsden 
et al 1975 p.230). 
5.4 AKATHISIA 
5.4.1 Incidence 
The incidence of akathisia in this study was 35% which compares 
favourably with other studies re:ported in the literature: Ratey 
and Salzman (1984) note that 20 to 45% of patients treated with 
neuroleptics may develop akathisia while Barnes and Braude 
(1985) found the incidence of akathisia in a group of 82 
psychiatric patients to be 35%. 
This result is clinically significant given that akathisia is 
reported to be one of the main factors leading to poor 
compliance with treatment programmes amongst psychiatric 
patients (Van Putten 1974). 
5.4.2 Age 
Akathisia has been reported to occur in most age groups of 
patients treated with neuroleptics (Marsden et al 1975 p.234), 
though Ayd (1961) described a higher incidence of akathisia in 
middle aged patients. The mean age of the 35 patients who 
developed akathisia in this study was 27,5 years. When 
attempting to interpret this, one must consider that 58% of the 
patients in this study were less than 30 years of age. It is 
possible that akathisia occurs commonly in young patients but 
is not routinely diagnosed. 
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5.4.3 Sex 
24 (35,8%) of the male patients in the study developed 
akathisia compared to 11 (33,3%) of the female patients. This 
difference is not statistically significant, but to reliably 
comment on this, a larger sample of patients would be required. 
There are no controlled studies reported in the literature that 
comment on the effect of gender on the ;incidence of akathisia. 
5.4.4 Drug treatment 
Patients treated with thioridazine had significantly lower 
scores for akathisia than those treated with the high potency 
drugs haloperidol and trifluoperazine (p = 0,0142). High 
potency drugs are more likely to produce akathisia than the low 
potency drugs such as thioridazine. In this study however, the 
doses of drugs used were not equal with haloperidol being used 
in much higher doses. 
Controlled studies (Van Putt en et al 1984) have however shown 
that haloperidol does produce a high incidence of akathisia 
compared to other neuroleptics. 
5.4.5 Phase of treatment 
Akathisia was seen to develop within 10 days of starting 
treatment with neuroleptics and often preceded the signs of 
parkinsonism. Van Putten et al (1984) reports that akathisia 
can occur within hours of starting treatment and is noticeable 
within days. Akathisia also occurs following increases in the 
dose of neuroleptic used (Braude et al 1983). These dose 
increases often occur during the first few weeks of treatment 
as was common in this study. 
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5 . 5 DYSTONIA 
5.5.1 Incidence 
The incidence of dystonia in this study was 20% which is 
comparable with other studies (using high and low potency 
neuroleptics) such as Stramek et al (1986) who found 20,9% of 
their patients developed dystonia following neuroleptic 
treatment. In studies using only high potency neuroleptics the 
incidence of dystonia has been reported to be as high as 94% 
(Boyer et al 1987). 
5.5.2 Age 
The mean age of the 20 patients who developed dystonic 
reactions was 25,8 years which included 16 patients under the 
age of 30 years. This trend supports the reported finding of 
a higher incidence of dystonia in young patients «30 years) 
receiving neuroleptic drug treatment (Swett 1975, Addonizio and 
Alexopoulos 1988). 
5.5.3 Sex 
14 (20,9%) of the male patients in the study developed dystonic 
reactions compared to 6 (18,2%) of the female patients. Though 
not statistically significant, slightly more males than females 
developed dystonic reactions. Swett (1975) reports that 
dystonic reactions are more commonly seen in young male 
patients receiving neuroleptic drugs. 
5.5.4 Drug treatment 
The high potency drugs haloperidol and trifluoperazine resulted 
in higher rates of dystonic reactions than chlorpromazine or 
thioridazine. No cases of dystonia were seen following 
treatment with thioridazine. This conforms with other studies 
done on the incidence of dystonia according to drug type (see 
section 2.3.4.3. page 14). 
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5.5.5 Phase of treatment 
85% of the cases of dystonia in this study developed within the 
first three days of treatment which is consistent with other 
studies on this subject: Stramek et al (1986) found that nearly 
90% of dystonic reactions occurred by the 3rd day of treatment 
while Ayd (1961) found that 90% of dystonic reactions developed 
within the first 4~ days. 
5.6 COMBINED NEUROLOGICAL SYNDROMES 
Patients treated with neuroleptics can develop more than one 
type of extrapyramidal syndrome. As has been noted by Donlon 
and Stenson (1976), Chakos et al (1992). In this study, 47% of 
the patients developed more than one syndrome with 9% of these 
patients having three syndromes. This is clinically 
significant as patients may suffer a great deal of distress as 
a result of these side effects. 
5.7 PRIOR HISTORY OF NEUROLOGICAL SIDE EFFECTS 
Of the 100 patients in this study, 46 gave a history of prior 
treatment with neuroleptic drugs. Of this group, 27 (59%) had 
developed neurological side effects as a result of their 
treatment. Of these 27 patents, 15 (56%) developed side 
effects in this study. This is not as high a correlation as 
was found in the study done by Keepers and Casey (1991) (see 
page 16) but indicates that a prior history of neurological 
side effects may predict an increased vulnerability on re-
exposure to neuroleptics. Clinicians should routin~ly ask 






The aim of this study was to discover the iI1cidence of acute 
neurological side effects in patients treated with neuroleptic 
drugs and to assess the factors responsible for these side 
effects. The limitations of this study and the conclusions 
derived from the results are presented below. 
6 . 2 LIMITATIONS OF THIS STUDY 
For the purposes of this study, a two week period was chosen to 
assess the development of acute neurological side effects 
following neuroleptic drug treatment. It is possible that this 
period was too short to fully observe the evolution of drug-
induced parkinsonism and akathisia. A study period of one month 
would have allowed a more extensive assessment of these 
particular side effects. This was however not possible in this 
study as a large percentage of the patients were discharged 
from hospital after 2 to 3 weeks of treatment. Another 
limiting factor was that patients who had not responded to 2 
weeks of treatment with a specific neuroleptic were often 
changed to an al ternati ve drug which complicated the assessment 
of drug-induced side effects. 
It was not possible to comment on the incidence of neurological 
side effects amongst elderly patients in this study due to the 
predominantly young patient population studied. Further studies 
on this subject should include more elderly patients to analyse 
the effect of age on the incidence of these side effects. 
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It was not possible to adequately assess the neurological side 
effects that resulted from the intramuscular drugs used in this 
study. The relatively small number of patients treated with a 
number of different neuroleptic drugs limited the statistical 
analysis. The results obtained, though not all statistically 
significant, did show trends which are clinically important. A 
larger study of more patients treated with a limited number of 
drugs would ensure a more comprehensive statistical analysis. 
6.3 CONCLUSIONS 
The incidence of drug-induced parkinsonism in this study was 
29%, akathisia 35% and dystonia 20%. Combinations of these 
three syndromes were observed resulting in an overall incidence 
of 47%. This represents a significant clinical problem with 
many implications for clinicians using neuroleptic drugs. 
Patients may experience physical discomfort and psychological 
distress due to these drug-induced side effects which may 
aggravate their psychiatric condition and lead to poor 
compliance with future treatment programmes (Van Putten 1974). 
Clinicians are often unaware of the problem and may misdiagnose 
or mistreat these side effects leading to many iatrogenic 
complications and unnecessary suffering by patients (Weiden et 
al 1987). 
In this study high potency drugs such as haloperidol and 
trifluoperazine were responsible for a large percentage of the 
side effects observed while of the low potency drugs, 
thioridazine produced less side effects than chlorpromazine. 
The mean daily dose of the different drugs was however unequal 
wi th haloperidol being used in comparatively higher doses. 
Oral drugs combined with intramuscular depot preparations 
resulted in a higher incidence of side effects than the oral 
drugs alone. 
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Careful selection of the type and dose of neuroleptic drug 
prescribed can minimise the chances of patients developing 
extrapyramidal side effects. The lowest effective dose of 
neuroleptic should be used where possible and more use should 
be made of drugs such as thioridazine which has relatively more 
anticholinergic properties than other neuroleptics resulting in 
less neurological side effects. 
The age and sex of the patients being treated should be taken 
into consideration when prescribing neuroleptics, given that 
these factors can influence the type of side effects that 
develop. Treatment regimes should be chosen specifically for 
the needs of individual patients which was not the case in the 
majority of patients in this study. 
The phase of treatment is also clinically important, as was 
seen in this study, with dystonia occurring more often within 
the first three days of treatment, akathisia within the first 
ten days and parkinsonism after ten to fourteen days. During 
this acute phase of treatment clinicians should examine their 
patients regularly to check for these specific side effects. 
Early detection and treatment of these frightening neurological 
syndromes will prevent unnecessary suffering and improve 
patients compliance with future treatment programmes. 
A thorough history and clinical examination for drug-induced 
side effects should be an important part of the psychiatric 
examination. Asking about neurological side effects 
encountered during previous treatments can be useful. In this 
study, 56% of patients who had a prior history of side effects 
developed similar problems on being re-exposed to neuroleptics. 
Regular questioning about feelings of stiffness, restlessness 
or unusual movements in patients can aid in the diagnosis of 
the early, subtle signs of parkinsonism, akathisia and 
dystonia. 
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Neuroleptic drugs play an important part in the treatment of 
psychiatric disorders, but clinicians should never ignore the 
patients quality of life while on treatment. Accurate early 
diagnosis and treatment of drug-induced side effects is 
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hereby consent to a Clinical examination for any acute 
neurological drug side effects. 
2. I acknowledge that I have been informed by Dr N Raymond 
concerning the possible advantages and possible adverse 
effects, which may result from the above mentioned 
procedure and of the ways in which it is different from 
the conventional procedure. 
3. I agree that the above procedure will be carried out and 
supervised by Dr N Raymond. 
4. I acknowledge that I understand the contents of this form 
and freely consent to the above procedure. 
5. I am aware that I may withdraw my consent at any time 







RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS 
1. Gai t - The patient is examined as he walks into the 
examining room, his gait, the swing of his arms, his 
general posture, all for the basis for an overall score 
for this item. This is rated as follows: 
o - normal 
1 - diminution in swing while the patient is walking 
2 - marked diminution in swing with obvious rigidity in 
the arm 
3 - stiff gait with arms held rigidly before the abdomen 
4 - stooped shuffling gait with propulsion and 
retropulsion 
2. Arm Dropping - The patient and the examiner both raise 
their arms to shoulder height and let them fall to their 
sides. In a normal subject a stout slap is heard as the 
arms hit the sides. In the patient with extreme 
Parkinson's syndrome the arms falls very slowly: 
o - normal, free fall with loud slap and rebound 
1 - fall slowed slightly with less audible contact and 
little rebound 
2 - fall slowed, no rebound 
3 - marked slowing, no slap at all 
4 - arms fall as though against resistance; as though 
through glue 
3. Shoulder shaking - The subject's arms are bent at a right 
angle at the elbow and are taken one at a time by the 
examiner who grasps one hand and also clasps the other 
around the patients' elbow. The subject's upper arm is 
pushed to and fro and the humerus is externally rotated. 
The degree of resistance from normal to extreme rigidity 
is scored as follows: 
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o - normal 
1 - slight stiffness and resistance 
2 - moderate stiffness and resistance 
3 - marked rigidity with difficulty in passive movement 
4 - extreme stiffness and rigidity with almost a frozen 
shoulder 
4. Elbow Rigidity - The elbow joints are separately bent at 
right angles and passively extended and flexed, with the 
subject's biceps observed and simultaneously palpated. 
The resistance to this procedure is rated. (The presence 
of cogwheel rigidity is noted separately.) Scoring is 
from 0-4 as in Shoulder Shaking test: 
o - normal 
1 - slight stiffness and resistance 
2 - moderate stiffness and resistance 
3 - marked rigidity with difficulty in passive movement 
4 - extreme stiffness and rigidity with almost a frozen 
elbow 
5. Fixation of position or wrist Rigidity - The wrist is held 
in one hand and the fingers held by the examiner's other 
hand, with the wrist moved to extension flexion and both 
ulner and radial deviation. The resistance to this 
procedure is rated as in Items 3 and 4: 
o - normal 
1 - slight stiffness and resistance 
2 - moderate stiffness and resistance 
3 marked rigidity with difficulty in passive movement 
4 - extreme stiffness and rigidity with almost a frozen 
wrist 
6. Leg Pendulousness - The patient sit's on a table with his 
legs hanging down and swinging free. The ankle is grasped 
by the examiner and raised until the knee is partially 
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extended. It is then allowed to fall. The resistance to 
falling and the lack of swing form the basis for the score 
on this item: 
o - the legs swing freely 
1 - slight diminution in the swing of the legs 
2 - moderate resistance to swing 
3 - marked resistance and damping of swing 
4 - complete absence of swing 
7. Head Dropping The patient lies on a well-padded 
examining table and his head is raised by the examiner's 
hand. The hand is then withdrawn and the head allowed to 
drop. In the normal subject the head will fall upon the 
table. The movement is delayed in extrapyramidal system 
disorder, and in extreme parkinsonism it is absent. The 
neck muscles are rigid and the head does not reach the 
examining table. Scoring is as follows: 
o - The head falls completely with a good thump as it hits 
the table 
1 - slight slowing in fall, mainly noted by lack of slap 
as head meets the table 
2 - moderate slowing in the fall quite noticeable to the 
eye 
3 - head falls stiffly and slowly 
4 - head does not reach examining table 
8. Glabella Tap - Subject is told to open his eyes wide and 
not to blink. The glabella region is tapped at a steady, 
rapid speed. The number of times patient blinks in 
succession is noted: 
o - 0-5 blinks 
1 - 6-10 blinks 
2 - 11-15 blinks 
3 - 16-20 blinks 
4 - 21 and more blinks 
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9. Tremor - Patient is observed walking into examining room 
and then is reexamined for this item: 
o - normal 
1 - mild finger tremor, obvious to sight and touch 
2 - tremor of hand or arm occurring spasmodically 
3 - persistent tremor of one or more limbs 
4 - whole body tremor 
10. Salivation - Patient is observed while talking and then 
asked to open his mouth and elevate his tongue. The 
following ratings are given: 
o - normal 
1 - excess salivation to the extent that pooling takes 
place if the mouth is open and tongue raised 
2 - when excess salivation is present and might 
occasionally result in difficulty in speaking 
3 - speaking with difficulty because of excess salivation 
4 - f~ank drooling 
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APPENDIX C 
RATING SCALE FOR DRUG-INDUCED AKATHISIA 
Patients should be observed while they are seated, and then 
standing while engaged in neutral conversation (for a minimum 
of two minutes in each position). Symptoms observed in other 
situations, for example, while engaged in activity phenomena 
should be elicited by direct questioning. 
OBJECTIVE 
o Normal, occasional fidgety movements of the limbs 
1 presence of characteristic restless movements: shuffling 
or tramping movements of the legs/feet, or swing of one 
leg, while sitting, and/or rocking from foot to foot or 
'walking on the spot'when standing, but movements present 
for less than half the time observed 
2 Observed phenomena, as described in (1) above, which are 
present for at least half the observation period 
3 The patient is constantly engaged in characteristic 
restless movements, and/or has the inability to remain 
seated or standing without walking or pacing, during the 
time observed 
SUBJECTIVE 
Awareness of restlessness 
o Absence of inner restlessness 
1 Non-specific sense of inner restlessness 
2 The patient is aware of an inability to keep the legs 
still, or a desire to move the legs, and/or complains of 
inner restlessness aggravated specifically by being 
required to stand still 
3 Awareness of an intense compulsion to move most of the 
time and/or reports a strong desire to walk or pace most 
of th~ time 
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Distress related to restlessness 




Global clinical assessment of akathisia 
o Absent 
No evidence of awareness of restlessness. Observation of 
characteristic movements of akathisia in the absence of a 
subjecti ve report of inner restlessness or compulsive 
desire to move the legs should be classified as 
pseudoakathisia 
1 Questionable 
Non-specific inner tension and fidgety movements 
2 Mild akathisia 
Awareness of restlessness in the legs and/or inner 
restlessness worse when required to stand still. Fidgety 
movements present but characteristic restless movements of 
akathisia not necessarily observed. Condi tion causes 
little or no distress 
3 Moderate akathisia 
Awareness of restlessness as described for mild akathisia 
above, combined with characteristic restless movements 
such as rocking from foot to foot when standing. Patient 
finds the condition distressing 
4 Marked akathisia 
Subjective experience of restlessness includes a 
compulsive desire to walk or pace, However, the patient 
is able to 
remain seated for a least five minutes. The condition is 
obviously distressing 
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5 Severe akathisia 
The patient reports a strong compulsion to pace Up and 
down most of the time. Unable to sit or lie down for more 
than a few minutes. constant restlessness which is 
associated with intense distress and insomnia 
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APPENDIX D 
DYSTONIA DATA SHEET 
Observation by examiner or ward staff of any dystonic 
movements. 
The type of movements should be described and the time of onset 




Onset: Day: hr 
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CHLORPROMAZINE EQUIVALENCE (mg/day) 
NUMBER 
3 
59 
YES/NO 
MAXIMUM 
SCORE 
4 
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